GORE® EXCLUDER® Endoprosthesis French Mandatory Registry
Study of the GORE® EXCLUDER® Endoprosthesis in the Treatment of Infra-renal Abdominal Aortic Aneurysms
This is a French Registry mandated by the French National Health Authority assessing long-term (5-years) safety of the GORE® Excluder® Endoprosthesis in the treatment of infra-renal Abdominal Aortic Aneurysms (AAA).
The use of abdominal aortic endoprostheses makes the treatment of infra-renal abdominal aortic aneurysms possible, with implantation via the femoral artery, thus avoiding a very invasive surgical procedure. The French National Authority for Health requires a 5-year follow-up as part of the renewal for reimbursement for these endoprostheses.
Observational [Patient Registry]
Percentage of Participants Survived at 5 Years
Percentage of Participants Free From Endoleak at 5 Years
Abdominal Aortic Aneurysm
GORE® EXCLUDER® Endoprosthesis
* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
October 5, 2018
Primary Completion Date
September 26, 2018
Inclusion Criteria: - Any patients requiring abdominal aortic stenting for the treatment of an unruptured infra-renal aortic abdominal aneurysm. Exclusion Criteria: - Patients whose clinical follow-up is not possible, i.eg, patient who cannot return for control visits (e.g. patients living abroad).
18 Years - N/A
Accepts Healthy Volunteers
Eric Steinmetz, Prof, ,
W.L.Gore & Associates
Eric Steinmetz, Prof, Principal Investigator, Centre Hospitalier Universitaire du Bocage